2018
DOI: 10.1021/acs.molpharmaceut.8b00592
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins

Abstract: Vaccines may offer a new treatment strategy for opioid use disorders and opioid-related overdoses. To speed translation, this study evaluates opioid conjugate vaccines containing components suitable for pharmaceutical manufacturing and compares analytical assays for conjugate characterization. Three oxycodone-based haptens (OXY) containing either PEGylated or tetraglycine [(Gly)4] linkers were conjugated to a keyhole limpet hemocyanin (KLH) carrier protein via carbodiimide (EDAC) or maleimide chemistry. The ED… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
55
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1
1

Relationship

6
4

Authors

Journals

citations
Cited by 43 publications
(57 citation statements)
references
References 66 publications
(213 reference statements)
2
55
0
Order By: Relevance
“…Thermal antinociception was tested on a 55 °C hot plate (IITC Life Scientific). Serum morphine were measured by gas chromatography coupled with mass spectrometry as previously described [ 52 , 53 ]. For additional details, see Supplementary Information .…”
Section: Methodsmentioning
confidence: 99%
“…Thermal antinociception was tested on a 55 °C hot plate (IITC Life Scientific). Serum morphine were measured by gas chromatography coupled with mass spectrometry as previously described [ 52 , 53 ]. For additional details, see Supplementary Information .…”
Section: Methodsmentioning
confidence: 99%
“…As an alternative or complementary option to MAT, anti-opioid vaccines are an emerging strategy to counteract OUD and overdose [9][10][11] . Active immunization with opioid-based small molecule haptens conjugated to immunogenic carriers elicit production of drug-specific polyclonal antibodies, which selectively bind to the target drug in the blood and prevent its distribution to the brain [12][13][14][15] . Preclinical studies have provided proof of efficacy, selectivity, and safety for this approach to reduce drug-seeking behavior and to prevent respiratory depression, bradycardia, and fatal overdose 14,[16][17][18][19][20] .…”
Section: Introductionmentioning
confidence: 99%
“…Serum was transferred to a 5 ml vial and stored at -20°C until analysis. Morphine concentrations were measured by gas chromatography coupled with mass spectrometry as previously described (31,32).…”
Section: Behavioral and Pharmacokinetic Assessmentsmentioning
confidence: 99%